Crossmark Global Holdings Inc. Buys 970 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Crossmark Global Holdings Inc. boosted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 23.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 5,083 shares of the specialty pharmaceutical company’s stock after buying an additional 970 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Jazz Pharmaceuticals were worth $567,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Versant Capital Management Inc boosted its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the period. Itau Unibanco Holding S.A. bought a new stake in Jazz Pharmaceuticals in the second quarter worth about $29,000. EverSource Wealth Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 55.1% during the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC grew its stake in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals in the second quarter worth approximately $33,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $121.65 on Friday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The firm’s fifty day simple moving average is $112.22 and its two-hundred day simple moving average is $110.35. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The firm has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a P/E/G ratio of 1.07 and a beta of 0.57.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on JAZZ. Wells Fargo & Company dropped their price objective on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. HC Wainwright restated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Finally, Piper Sandler decreased their price target on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.00.

Insider Buying and Selling

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock worth $720,160 in the last ninety days. 4.20% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.